Pulse Biosciences, Inc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Paul A. LaViolette
- Full Time Employees
- 116
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 601 Brickell Key Drive Miami FL United States 33131
- IPO Date
- May 18, 2016
- CIK
- 0001625101
- Website
- pulsebiosciences.com
- Similar Companies
- Business
- Pulse Biosciences, Inc. engages in the development and commercialization of innovative bioelectric technology platforms for use in medical aesthetic and oncology applications. The company's core products include the Nano-Pulse Stimulation (NPS) platform and the CellFX System, which deliver ultrashort electrical pulses to target and treat various cellular abnormalities. These technologies are employed for aesthetic procedures such as the treatment of sebaceous hyperplasia, warts, and other dermatological conditions, as well as for emerging oncology indications. Pulse Biosciences offers its products primarily in the United States, with operations extending to selected international markets. Founded in 2011, the company is headquartered in Hayward, California. In terms of recent developments within the last 1-2 years, Pulse Biosciences has focused on expanding the applications of its NPS technology through clinical trials and regulatory progress towards new indications, including oncology treatments. The company has made strategic partnerships and commenced new clinical evaluations to broaden the commercial use of its CellFX System. These initiatives mark a significant expansion beyond its initial dermatology and medical aesthetics focus, emphasizing the company's commitment to advancing innovative, non-thermal, tissue-selective therapies. There have been no major name changes or reorganizations reported recently, but the company continues to align its product development with evolving market needs in both aesthetic medicine and oncology. Pulse Biosciences operates in the medical technology industry, specifically within the segments of medical aesthetics and oncology device manufacturing. Its target markets include dermatology clinics, medical aesthetic centers, and oncology treatment facilities. The company develops and sells its products through direct sales and partnerships, aiming to provide minimally invasive treatment options that reduce patient downtime and side effects compared to conventional treatments. In summary, Pulse Biosciences, Inc. specializes in the manufacture and commercialization of bioelectric pulse-mediated medical technologies such as the CellFX System and related products, serving aesthetic and oncology markets with innovative tissue-targeting therapies primarily in the United States and internationally. Its ongoing clinical and commercial expansion efforts and strategic partnerships highlight the company's focus on broadening the applications of its proprietary bioelectric technology platform. The company was established in 2011 and is headquartered in Hayward, California. [web:search results synthesized]
Company News
Varex Imaging (NASDAQ:VREX) vs. Pulse Biosciences (NASDAQ:PLSE) Head to Head Review
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences' nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026
Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
Pulse Biosciences, Inc (NASDAQ:PLSE) Stock Has Average Price Target of $50.20
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Why Pulse Biosciences Stock Popped Today
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Deutsche Bank AG Takes Position in Pulse Biosciences, Inc $PLSE
Bank of America Corp DE Grows Stake in Pulse Biosciences, Inc $PLSE
Pulse Biosciences (NASDAQ:PLSE) Sets New 1-Year High – Here’s Why
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform
Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript
Pulse Biosciences Q2 Earnings Call Highlights
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue Estimates
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results